1. Patients who received statin therapy using a treat-to-target approach (targeting LDL-cholesterol of 50-70mg/dL) did not have worse cardiovascular outcomes ...
![Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/800px-RCA_atherosclerosis-350x250.jpg)
1. Olpasiran significantly and substantially reduced lipoprotein(a) concentration in patients with atherosclerotic cardiovascular disease compared to placebo. 2. Olpasiran reduced ...
1. A significantly greater proportion of patients receiving 2-3 lipid lowering medications achieved LDL-cholesterol targets compared to those receiving monotherapy. ...
1. In this study, improved sleep quality was associated with significantly decreased systolic blood pressure and increased high-density lipoprotein levels ...
1. In individuals aged 70-100 years, there was a significantly increased risk of myocardial infarction and atherosclerotic cardiovascular disease for ...
1. In patients aged ≥75 years, LDL cholesterol-lowering therapies reduced the risk for major vascular events, including cardiovascular death, myocardial ...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did ...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did ...
1. Targeting a lower LDL does not impact carotid plaque incidence but does increase the rate of regression of pre-existing ...
Click to read the study in JAHA Image: PD ©2020 2 Minute Medicine, Inc. All rights reserved. No works may ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.